The Clinical Significance Of The Detection Of Chemotherapy Drug Sensitivity In Patients With Osteosarcoma And Soft Tissue Sarcoma.

e23505 Background: Osteosarcoma and soft tissue sarcoma have low sensitivity to chemotherapy and are prone to recurrence and metastasis. In order to improve the efficacy of chemotherapy, we decided to investigate the expression of drug sensitive indicator genes in tumor tissue of patients. By analyzing the association between target gene expression and drug sensitivity results, we may establish a more accurate and effective chemotherapy guidance for clinical practice. Methods: This study included 20 patients with osteosarcoma and 36 patients with soft tissue sarcoma who were treated in the Department of Clinical Oncology of Xijing hospital from October 2014 to June 2016. Half of the patients from each tumor group received drug sensitivity test using liquid chip technology in tumor tissue specimens to predict genes indicating chemotherapy drug sensitivity (including platinum sensitivity index of ERCC1 and BRCA1; drug sensitivity index of TYMS and RRM1 for fluorine, pemetrexed, capecitabine and gemcitabine; docetaxel sensitivity index of TUBB3 and STMN1; etoposide and anthracycline sensitivity index of TOP2A). The patients were followed up to May 2017.Disease or progression free survival (DFS/PFS) was recorded after the application of the sensitive drugs. Results: Among 20 patients with osteosarcoma and 36 patients with soft tissue sarcomas, there is no difference in age, stage and tumor primary site between drug sensitivity test group and routine group(P > 0.05). In Osteosarcoma, DFS in drug sensitivity group was significantly higher than that in routine group (8.0±2.18 months and 4.0±1.31 months, P = 0.032). However, for soft tissue sarcomas, there is no statistical difference between the drug sensitivity group and routine group in DFS/PFS (13.0±2.64 months and 14±2.39 months respectively, P = 0.839). Conclusions: From the “one size fits all” treatment strategy to personalized precision medicine, it requires new strategies to predict drug sensitivity in individual. The drug sensitivity testwith gene expression profiling can provide an effective approach to improve the chemotherapeutic efficacy for mesenchymal malignant tumors, especially for osteosarcoma.